Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
7.98
+0.08 (1.01%)
Dec 5, 2025, 4:00 PM EST - Market closed
Gyre Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Cash & Equivalents | 40.4 | 11.81 | 33.51 | 25.18 |
| Short-Term Investments | 19.65 | 14.86 | - | - |
| Cash & Short-Term Investments | 60.05 | 26.67 | 33.51 | 25.18 |
| Cash Growth | 139.31% | -20.41% | 33.10% | - |
| Accounts Receivable | 25.88 | 19.59 | 15.16 | 15.61 |
| Other Receivables | 0.23 | 5.19 | 1.29 | - |
| Receivables | 26.8 | 29.15 | 16.84 | 17.14 |
| Inventory | 8.85 | 6.34 | 4.28 | 6.12 |
| Prepaid Expenses | 2.87 | 1.19 | 1.55 | 0.38 |
| Other Current Assets | - | 1.44 | 1.05 | 0.84 |
| Total Current Assets | 98.58 | 64.79 | 57.22 | 49.65 |
| Property, Plant & Equipment | 24.91 | 25.7 | 23.78 | 18.38 |
| Long-Term Investments | 20.32 | 24.57 | 23.43 | 7.39 |
| Other Intangible Assets | 4.85 | 1.71 | 1.7 | 1.86 |
| Long-Term Deferred Tax Assets | 6.71 | 5.62 | 4.7 | 4.08 |
| Other Long-Term Assets | 4.02 | 3.03 | 5.72 | 3.39 |
| Total Assets | 159.38 | 125.41 | 116.54 | 84.75 |
| Accounts Payable | 0.56 | 0.11 | 0.36 | 0.12 |
| Accrued Expenses | 9.46 | 9.3 | 10.56 | 6.77 |
| Current Portion of Leases | 0.63 | 0.71 | 0.21 | 0.49 |
| Current Income Taxes Payable | 2.65 | 2.83 | 5.05 | 2.1 |
| Current Unearned Revenue | 0.15 | 0.16 | 0.08 | 0.17 |
| Other Current Liabilities | 2.47 | 6.41 | 3.79 | 2.59 |
| Total Current Liabilities | 15.91 | 19.52 | 20.05 | 12.24 |
| Long-Term Leases | 0.54 | 0.89 | 0.2 | 0.12 |
| Long-Term Unearned Revenue | 0.87 | 0.93 | 0.21 | 0.12 |
| Other Long-Term Liabilities | 4.65 | 5.68 | 17.61 | 0.06 |
| Total Liabilities | 21.97 | 27 | 38.07 | 12.54 |
| Common Stock | 0.09 | 0.09 | 0.08 | 0.06 |
| Additional Paid-In Capital | 167.13 | 136.19 | 68.18 | 32.8 |
| Retained Earnings | -63.61 | -70.36 | -82.44 | 10.06 |
| Comprehensive Income & Other | -1.7 | -2.6 | -1.64 | -0.39 |
| Total Common Equity | 101.92 | 63.32 | -15.83 | 42.52 |
| Minority Interest | 35.5 | 35.08 | 29.78 | 29.7 |
| Shareholders' Equity | 137.42 | 98.4 | 78.47 | 72.22 |
| Total Liabilities & Equity | 159.38 | 125.41 | 116.54 | 84.75 |
| Total Debt | 1.17 | 1.6 | 0.41 | 0.61 |
| Net Cash (Debt) | 58.88 | 25.07 | 33.1 | 24.56 |
| Net Cash Growth | 152.75% | -24.25% | 34.76% | - |
| Net Cash Per Share | 0.57 | 0.25 | 0.50 | 0.32 |
| Filing Date Shares Outstanding | 90.89 | 93.61 | 85.42 | 63.59 |
| Total Common Shares Outstanding | 90.89 | 86.31 | 76.6 | 63.59 |
| Working Capital | 82.66 | 45.27 | 37.17 | 37.41 |
| Book Value Per Share | 1.12 | 0.73 | -0.21 | 0.67 |
| Tangible Book Value | 97.07 | 61.61 | -17.53 | 40.67 |
| Tangible Book Value Per Share | 1.07 | 0.71 | -0.23 | 0.64 |
| Buildings | 19.23 | 18.98 | 12.29 | 10.84 |
| Machinery | 10.47 | 10.28 | 7.39 | 5.69 |
| Construction In Progress | 0.84 | 0.22 | 7.88 | 4.85 |
| Leasehold Improvements | - | - | - | 0.33 |
Source: S&P Capital IQ. Standard template. Financial Sources.